Health Health News

Dr Reddy’s launches Avigan (Favipiravir) in India for COVID-19

Dr. Reddy’s Laboratories launches generic Ocaliva in domestic market

Dr. Reddy’s Laboratories Ltd. today announced the launch of AVIGAN (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co. Ltd. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute the Tablets in India.

            AVIGAN  (Favipiravir) has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease.

            M V Ramana, Chief Executive Officer, Branded Markets, Dr. Reddy’s Laboratories, said “We are pleased to bring this important innovator medicine to the patients in India. The need for high quality and efficacy, affordability and better disease management are key priorities for us. We believe that AVIGAN would provide an effective treatment option to the COVID-19 impacted patients in India.”

AVIGAN comes in a complete therapy pack of 122 tablets with a two-year shelf life. To ensure accelerated access to the medicine, Dr. Reddy’s has initiated a free home delivery service in 42 cities in the country, and a Helpline Center  between 9 am to 9pm IST , Monday through Saturday.

Related posts

AP Gets One Lakh Rapid COVID-19 Testing Kits from South Korea


Kamineni Fertility Centre celebrates 10th anniversary


Pathancheruvu MLA Mahipal Reddy tests positive


Leave a Comment

Real emotions of real people from Bali